Related Experiment Video

Updated: Jul 3, 2025

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.0K

Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

Taiwo Adesoye1, Debasish Tripathy2, Kelly K Hunt1

  • 1Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancers
|February 10, 2024
PubMed

Insights

Signal Transducer and Activator of Transcription 3 (STAT3) is crucial for cell functions but its dysregulation drives cancer. This review explores STAT3 mechanisms, its role in cancer, and novel therapeutic strategies targeting STAT3 for clinical application.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Signal Transducer and Activator of Transcription 3 (STAT3) is a key transcription factor regulating cell proliferation, differentiation, angiogenesis, and survival.
  • STAT3 activation involves complex phosphorylation events initiated by upstream kinases, tightly controlling downstream gene expression.
  • Aberrant STAT3 activation is implicated in the development and progression of various cancers, including tumorigenesis, metastasis, and recurrence.

Purpose of the Study:

  • To review the intricate mechanisms of STAT3 activation and its downstream effects in both physiological and malignant contexts.
  • To outline current and emerging therapeutic strategies aimed at targeting STAT3 for cancer treatment.
  • To summarize pre-clinical and clinical evidence for novel STAT3-targeting drugs and discuss challenges in their clinical implementation.

Main Methods:

  • Literature review of STAT3 signaling pathways.
  • Analysis of STAT3's role in normal cellular processes and cancer development.
  • Synthesis of data on pre-clinical and clinical studies of STAT3 inhibitors.

Main Results:

  • STAT3's dual role in normal physiology and cancer pathogenesis is detailed.
  • Various upstream activators and downstream targets of STAT3 are identified.
  • Evidence for the efficacy and limitations of novel STAT3-targeting drugs is presented.

Conclusions:

  • STAT3 is a critical mediator in cellular processes and a significant driver of cancer.
  • Targeting STAT3 presents a promising therapeutic avenue for multiple cancers.
  • Further research and clinical development are necessary to overcome challenges and establish the therapeutic efficacy of STAT3 inhibitors.
Keywords:
STAT3cancertherapeutics

More Related Videos

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

3.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

95

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K